Alemtuzumab in multiple sclerosis: Mechanism of action and beyond

International Journal of Molecular Sciences

Volumn 16, Issue 7, 2015, Pages 16414-16439

  Ruck, Tobias ^a   Bittner, Stefan ^a   Wiendl, Heinz ^a   Meuth, Sven G ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Alemtuzumab; CD52; Experimental autoimmune encephalomyelitis (EAE); Mechanism of action; Multiple sclerosis; Secondary autoimmune disease

Indexed keywords

ALEMTUZUMAB; BETA1A INTERFERON; INTERLEUKIN 21; INTERLEUKIN 7; MONOCLONAL ANTIBODY;

DISEASE ACTIVITY; DRUG MECHANISM; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; GLOMERULONEPHRITIS; HUMAN; INFECTION; INFUSION RELATED REACTION; MULTIPLE SCLEROSIS; NONHUMAN; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; RECURRENCE RISK; REVIEW; THROMBOCYTOPENIA; THYROID DISEASE; ANIMAL; CLINICAL TRIAL (TOPIC); IMMUNOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CLINICAL TRIALS AS TOPIC; HUMANS; MULTIPLE SCLEROSIS;

EID: 84937501642     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms160716414     Document Type: Review

References (105)

1. Havrdova, E.; Horakova, D.; Kovarova, I. Alemtuzumab in the treatment of multiple sclerosis: Key clinical trial results and considerations for use. Ther. Adv. Neurol. Disord. 2015, 8, 31–45.
2. Menge, T.; Stuve, O.; Kieseier, B.C.; Hartung, H.P. Alemtuzumab: The advantages and challenges of a novel therapy in MS. Neurology 2014, 83, 87–97.
3. Wiendl, H.; Kieseier, B. Multiple sclerosis: Reprogramming the immune repertoire with alemtuzumab in MS. Nat. Rev. Neurol. 2013, 9, 125–126.
4. Boulianne, G.L.; Hozumi, N.; Shulman, M.J. Production of functional chimaeric mouse/human antibody. Nature 1984, 312, 643–646.
5. Klotz, L.; Meuth, S.G.; Wiendl, H. Immune mechanisms of new therapeutic strategies in multiple sclerosis—A focus on alemtuzumab. Clin. Immunol. 2012, 142, 25–30.
6. Rodig, S.J.; Abramson, J.S.; Pinkus, G.S.; Treon, S.P.; Dorfman, D.M.; Dong, H.Y.; Shipp, M.A.; Kutok, J.L. Heterogeneous CD52 expression among hematologic neoplasms: Implications for the use of alemtuzumab (Campath-1H). Clin. Cancer Res. 2006, 12, 7174–7179.
7. Ginaldi, L.; de Martinis, M.; Matutes, E.; Farahat, N.; Morilla, R.; Dyer, M.J.; Catovsky, D. Levels of expression of CD52 in normal and leukemic B and T cells: Correlation with in vivo therapeutic responses to Campath-1H. Leuk. Res. 1998, 22, 185–191.
8. Hale, G. The CD52 antigen and development of the Campath antibodies. Cytotherapy 2001, 3, 137–143.
9. Xia, M.Q.; Tone, M.; Packman, L.; Hale, G.; Waldmann, H. Characterization of the Campath-1 (CDw52) antigen: Biochemical analysis and cDNA cloning reveal an unusually small peptide backbone. Eur. J. Immunol. 1991, 21, 1677–1684.
10. Rowan, W.C.; Hale, G.; Tite, J.P.; Brett, S.J. Cross-linking of the Campath-1 antigen (CD52) triggers activation of normal human T lymphocytes. Int. Immunol. 1995, 7, 69–77.
11. Masuyama, J.; Yoshio, T.; Suzuki, K.; Kitagawa, S.; Iwamoto, M.; Kamimura, T.; Hirata, D.; Takeda, A.; Kano, S.; Minota, S. Characterization of the 4C8 antigen involved in transendothelial migration of CD26(hi) T cells after tight adhesion to human umbilical vein endothelial cell monolayers. J. Exp. Med. 1999, 189, 979–990.
12. Watanabe, T.; Masuyama, J.; Sohma, Y.; Inazawa, H.; Horie, K.; Kojima, K.; Uemura, Y.; Aoki, Y.; Kaga, S.; Minota, S., et al. CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells. Clin. Immunol. 2006, 120, 247–259.
13. Bandala-Sanchez, E.; Zhang, Y.; Reinwald, S.; Dromey, J.A.; Lee, B.H.; Qian, J.; Bohmer, R.M.; Harrison, L.C. T cell regulation mediated by interaction of soluble CD52 with the inhibitory receptor Siglec-10. Nat. Immunol. 2013, 14, 741–748.
14. Maloy, K.J.; Powrie, F. Regulatory T cells in the control of immune pathology. Nat. Immunol. 2001, 2, 816–822.
15. Long, S.A.; Buckner, J.H. CD4+FoxP3+ T regulatory cells in human autoimmunity: More than a numbers game. J. Immunol. 2011, 187, 2061–2066.
16. Tuohy, O.; Costelloe, L.; Hill-Cawthorne, G.; Bjornson, I.; Harding, K.; Robertson, N.; May, K.; Button, T.; Azzopardi, L.; Kousin-Ezewu, O., et al. Alemtuzumab treatment of multiple sclerosis: Long-term safety and efficacy. J. Neurol. Neurosurg. Psychiatry 2015, 86, 208–215.
17. Rao, S.P.; Sancho, J.; Campos-Rivera, J.; Boutin, P.M.; Severy, P.B.; Weeden, T.; Shankara, S.; Roberts, B.L.; Kaplan, J.M. Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis. PLoS ONE 2012, 7, e39416.
18. Hu, Y.; Turner, M.J.; Shields, J.; Gale, M.S.; Hutto, E.; Roberts, B.L.; Siders, W.M.; Kaplan, J.M. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology 2009, 128, 260–270.
19. Jones, D.E.; Goldman, M.D. Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis: A review of its clinical pharmacology, efficacy and safety. Expert Rev. Clin. Immunol. 2014, 10, 1281–1291.
20. Coles, A.J.; Cox, A.; Le Page, E.; Jones, J.; Trip, S.A.; Deans, J.; Seaman, S.; Miller, D.H.; Hale, G.; Waldmann, H., et al. The window of therapeutic opportunity in multiple sclerosis: Evidence from monoclonal antibody therapy. J. Neurol. 2006, 253, 98–108.
21. Thompson, S.A.; Jones, J.L.; Cox, A.L.; Compston, D.A.; Coles, A.J. B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis. J. Clin. Immunol. 2010, 30, 99–105.
22. Jones, J.L.; Phuah, C.L.; Cox, A.L.; Thompson, S.A.; Ban, M.; Shawcross, J.; Walton, A.; Sawcer, S.J.; Compston, A.; Coles, A.J. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J. Clin. Investig. 2009, 119, 2052–2061.
23. Coles, A.J.; Wing, M.G.; Molyneux, P.; Paolillo, A.; Davie, C.M.; Hale, G.; Miller, D.; Waldmann, H.; Compston, A. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann. Neurol. 1999, 46, 296–304.
24. Investigators, C.T.; Coles, A.J.; Compston, D.A.; Selmaj, K.W.; Lake, S.L.; Moran, S.; Margolin, D.H.; Norris, K.; Tandon, P.K. Alemtuzumab vs. Interferon β-1a in early multiple sclerosis. N. Engl. J. Med. 2008, 359, 1786–1801.
25. Coles, A.J.; Fox, E.; Vladic, A.; Gazda, S.K.; Brinar, V.; Selmaj, K.W.; Bass, A.D.; Wynn, D.R.; Margolin, D.H.; Lake, S.L., et al. Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: Post-hoc and subset analyses of clinical efficacy outcomes. Lancet Neurol. 2011, 10, 338–348.
26. Cohen, J.A.; Coles, A.J.; Arnold, D.L.; Confavreux, C.; Fox, E.J.; Hartung, H.P.; Havrdova, E.; Selmaj, K.W.; Weiner, H.L.; Fisher, E., et al. Alemtuzumab versus interferon β 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: A randomised controlled phase 3 trial. Lancet 2012, 380, 1819–1828.
27. Coles, A.J.; Twyman, C.L.; Arnold, D.L.; Cohen, J.A.; Confavreux, C.; Fox, E.J.; Hartung, H.P.; Havrdova, E.; Selmaj, K.W.; Weiner, H.L., et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: A randomised controlled phase 3 trial. Lancet 2012, 380, 1829–1839.
28. Hartung, H.P.; Aktas, O.; Boyko, A.N. Alemtuzumab: A new therapy for active relapsing-remitting multiple sclerosis. Mult. Scler. 2015, 21, 22–34.
29. Coles, A.J.; Fox, E.; Vladic, A.; Gazda, S.K.; Brinar, V.; Selmaj, K.W.; Skoromets, A.; Stolyarov, I.; Bass, A.; Sullivan, H., et al. Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology 2012, 78, 1069–1078.
30. Havrdova, E.; Giovannoni, G.; Arnold, D.L.; Coles, A.J.; Fox, E.J.; Hartung, H.; Selmaj, K.W.; Margolin, D.H.; Palmer, J.; Panzara, M., et al. Durable effect of alemtuzumab on clinical outcomes in patients with relapsing-remitting multiple sclerosis who relapsed on prior therapy: 4-Year follow-up of CARE-MS II. In Proceedings of the AAN Meeting, Philadelphia, PA, USA, 26 April–3 May 2014.
31. Compston, D.A.S.; Giovannoni, G.; Arnold, D.L.; Fox, E.J.; Hartung, H.; Havrdova, E.; Selmaj, K.W; Margolin, D.H.; Palmer, J.; Panzara, M., et al. Durable effect of alemtuzumab on clinical outcomes in treatment-naive relapsing-remitting multiple sclerosis patients: 4-Year follow-up of CARE-MS I. In Proceedings of the AAN Meeting, Philadelphia, PA, USA, 26 April–3 May 2015.
32. LaGanke, C.; Hughes, B.; Berkovich, R.; Cohen, J.A.; Giovannoni G.; Kasten, L.; Margolin, D.H.; Havrdova, E. Durable effect of alemtuzumab on disability improvement in patients with relapsing-remitting multiple sclerosis who relapsed on a prior therapy. In Proceedings of the AAN Meeting, Washington, DC, USA, 18–25 April 2015.
33. Coles, A.J.; Arnold, D.L.; Cohen, J.A.; Fox, E.J.; Hartung, H.; Havrdova, E.; Selmaj, K.W.; Margolin, D.H.; Kasten, L.; Panzara, M., et al. Alemtuzumab slows brain volume loss over 4 years despite most relapsing-remitting multiple sclerosis patients not receiving treatment for 3 years. In Proceedings of the AAN Meeting, Washington, DC, USA, 18–25 April 2015.
34. Traboulsee, A.; Coles, A.J.; Cohen, J.A.; Compston, D.A.S.; Fox, E.J.; Hartung, H.; Havrdova, E.; Selmaj, K.W.; Margolin, D.H.; Zhao, Y., et al. Durable effect of alemtuzumab on MRI outcomes in patients with relapsing-remitting multiple sclerosis who relapsed on prior therapy: 4-Year follow-up of CARE-MS II. In Proceedings of the AAN Meeting, Washington, DC, USA, 18–25 April 2015.
35. Arnold, D.L.; Traboulsee, A.; Coles, A.J.; Cohen, J.A.; Fox, E.J.; Hartung, H.; Havrdova, E.; Selmaj, K.W.; Margolin, D.H.; Zhao, Y., et al. Durable effect of alemtuzumab on MRI activity in treatment-naive active relapsing-remitting multiple sclerosis patients: 4-Year follow-up of CARE-MS I. In Proceedings of the AAN Meeting, Washington, DC, USA, 18–25 April 2015.
36. Hartung, H.; Giovannoni, G.; Arnold, D.L.; Coles, A.J.; Fox, E.J.; Havrdova, E.; Selmaj, K.W.; Margolin, D.H.; Compston, D.A.S. Improvement in clinical outcomes in treatment-naive relapsing-remitting multiple sclerosis patients who switched from subcutaneous interferon β-1a to alemtuzumab. In Proceedings of the AAN Meeting, Washington, DC, USA, 18–25 April 2015.
37. Fox, E.J.; Giovannoni, G.; Arnold, D.L.; Coles, A.J.; Hartung, H.; Havrdova, E.; Selmaj, K.W.; Margolin, D.H.; Compston, D.A.S. Improvement in clinical outcomes following switch from subcutaneous interferon β-1a to alemtuzumab: CARE-MS II extension study. In Proceedings of the AAN Meeting, Washington, DC, USA, 18–25 April 2015.
38. Barkhof, F.; Pelletier, D.; Coles, A.J.; Cohen, J.A.; Compston, D.A.S.; Fox, E.J.; Hartung, H.; Havrdova, E.; Margolin, D.H.; Kasten, L., et al. Switching to alemtuzumab from subcutaneous interferon β-1a after CARE-MS I further improved MRI outcomes in patients with relapsing-remitting multiple sclerosis. In Proceedings of the AAN Meeting, Washington, DC, USA, 18–25 April 2015.
39. Pelletier, D.; Barkhof, F.; Coles, A.J.; Cohen, J.A.; Compston, D.A.S.; Fox, E.J.; Hartung, H.; Havrdova, E.; Margolin, D.H.; Kasten, L., et al. Switching to alemtuzumab from subcutaneous interferon β-1a after CARE-MS II further improved MRI outcomes in patients with relapsing-remitting multiple sclerosis. In Proceedings of the AAN Meeting, Washington, DC, USA, 18–25 April 2015.
40. Cohen, J.A.; Arnold, D.L.; Coles, A.J.; Fox, E.J.; Hartung, H.; Havrdova, E.; Selmaj, K.W.; Margolin, D.H.; Kasten, L.; Compston, D.A.S. Slowing of brain volume loss in patients with relapsing-remitting multiple sclerosis after switching from subcutaneous interferon β-1a to alemtuzumab. In Proceedings of the AAN Meeting, Washington, DC, USA, 18–25 April 2015.
41. Breslin, S. Cytokine-release syndrome: Overview and nursing implications. Clin. J. Oncol. Nurs. 2007, 11, 37–42.
42. Maggi, E.; Vultaggio, A.; Matucci, A. Acute infusion reactions induced by monoclonal antibody therapy. Expert Rev. Clin. Immunol. 2011, 7, 55–63.
43. Mayer, L.; Casady, L.; Clayton, G.; Oyuela, P.; Margolin, D. Alemtuzumab infusion-associated reactions and management in multiple sclerosis. J. Infus. Nurs. Manag. (Harrow) 2014, 37, 250–258.
44. Wray, S.; Boyko, A.N.; Braley, T.J.; Khan, O.; Margolin, D.H.; Coles, A.J. Administration of alemtuzumab on nonconsecutive days does not impact infusion-associated reactions, efficacy, or lymphocyte depletion. In Proceedings of the AAN Meeting, Washington, DC, USA, 18–25 April 2015.
45. Vermersch, P.; Vanopdenbosch, L.J.; González, R.A.; Fernandez, O.; Baldinetti, F.; Krolczyk, S.; Martell, L.; Moreau, T. Evaluation of comprehensive alemtuzumab infusion guidance in patients with relapsing-remitting multiple sclerosis: Emerald study design. In Proceedings of the AAN Meeting, Washington, DC, USA, 18–25 April 2015.
46. Wray, S.; Arnold, D.L.; Cohen, J.; Coles, A.; Fox, E.; Hartung, H. Herpes infection risk reduced with acyclovir prophylaxis after alemtuzumab. In Proceedings of the Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC), Orlando, FL, USA, 27–30 May 2013.
47. Henson, L.J.; Arnold, D.L.; Cohen, J.A.; Coles, A.J.; Fox, E.J.; Hartung, H.; Havrdova, E.; Selmaj, K.W.; Margolin, D.H.; Compston, D.A.S. Incidence of infection decreases over time in alemtuzumab-treated patients with relapsing-remitting multiple sclerosis: 4-year follow-up of the CARE-MS studies. In Proceedings of the AAN Meeting, Washington, DC, USA, 18–25 April 2015.
48. Buggins, A.G.; Mufti, G.J.; Salisbury, J.; Codd, J.; Westwood, N.; Arno, M.; Fishlock, K.; Pagliuca, A.; Devereux, S. Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab. Blood 2002, 100, 1715–1720.
49. McCarthy, C.L.; Tuohy, O.; Compston, D.A.; Kumararatne, D.S.; Coles, A.J.; Jones, J.L. Immune competence after alemtuzumab treatment of multiple sclerosis. Neurology 2013, 81, 872–876.
50. Clark, R.A.; Watanabe, R.; Teague, J.E.; Schlapbach, C.; Tawa, M.C.; Adams, N.; Dorosario, A.A.; Chaney, K.S.; Cutler, C.S.; Leboeuf, N.R., et al. Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated ctcl patients. Sci. Transl. Med. 2012, 4, 117-117.
51. Miller, T.; Habek, M.; Coles, A.; Selmaj, K.; Margolin, D.; Palmer, J. Analysis of data from rrms alemtuzumab-treated patients in the clinical program to evaluate incidence rates of malignancy. In Proceedings of the Join ACTRIMS-ECTRIMS Meeting, Boston, MA, USA, 10–13 September 2014.
52. Alemtuzumab prescribing information. Available online: http://www.Accessdata.Fda.Gov/drugsatfda_docs/label/2014/103948s5139lbl.Pdf (accessed on 4 May 2015).
53. McCombe, P.; Achiron, A.; Giovannoni, G.; Brinar, V.; Margolin, D.; Palmer, J. Pregnancy outcomes in the alemtuzumab multiple sclerosis clinical development program. In Proceedings of the Join ACTRIMS-ECTRIMS Meeting, Boston, MA, USA, 10–13 September 2014.
54. Margolin, D.; Rizzo, M.; Smith, G.; Arnold, D.; Coles, A.; Hartung, H. Alemtuzumab treatment has no adverse impact on sperm quality, quantity, or motility: A care-MS substudy. In Proceedings of the 21st World Congress of Neurology, Vienna, Austria, 21–26 September 2013.
55. Daniels, G.H.; Vladic, A.; Brinar, V.; Zavalishin, I.; Valente, W.; Oyuela, P.; Palmer, J.; Margolin, D.H.; Hollenstein, J. Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis. J. Clin. Endocrinol. Metab. 2014, 99, 80–89.
56. Jones, J.L.; Thompson, S.A.; Loh, P.; Davies, J.L.; Tuohy, O.C.; Curry, A.J.; Azzopardi, L.; Hill-Cawthorne, G.; Fahey, M.T.; Compston, A., et al. Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation. Proc. Natl. Acad. Sci. USA 2013, 110, 20200–20205.
57. Hunter, S.F.; Arnold, D.L.; Coles, A.J.; Cohen, J.A.; Fox, E.J.; Hartung, H.; Havrdova, E.; Margolin, D.H.; Compston, D.A.S.; on behalf of the CARE-MS Investigators. The efficacy of alemtuzumab is maintained in patients who develop thyroid adverse events. In Proceedings of the AAN Meeting, Washinton, DC, USA, 18–25 April 2015.
58. Krupica, T., Jr.; Fry, T.J.; Mackall, C.L. Autoimmunity during lymphopenia: A two-hit model. Clin. Immunol. 2006, 120, 121–128.
59. Zandman-Goddard, G.; Shoenfeld, Y. HIV and autoimmunity. Autoimmun. Rev. 2002, 1, 329–337.
60. Powrie, F.; Leach, M.W.; Mauze, S.; Caddle, L.B.; Coffman, R.L. Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice. Int. Immunol. 1993, 5, 1461–1471.
61. Yang, L.; Anderson, D.E.; Baecher-Allan, C.; Hastings, W.D.; Bettelli, E.; Oukka, M.; Kuchroo, V.K.; Hafler, D.A. IL-21 and TGF-β are required for differentiation of human T(h)17 cells. Nature 2008, 454, 350–352.
62. Ettinger, R.; Sims, G.P.; Fairhurst, A.M.; Robbins, R.; da Silva, Y.S.; Spolski, R.; Leonard, W.J.; Lipsky, P.E. IL-21 induces differentiation of human naive and memory b cells into antibody-secreting plasma cells. J. Immunol. 2005, 175, 7867–7879.
63. Clough, L.E.; Wang, C.J.; Schmidt, E.M.; Booth, G.; Hou, T.Z.; Ryan, G.A.; Walker, L.S. Release from regulatory T cell-mediated suppression during the onset of tissue-specific autoimmunity is associated with elevated IL-21. J. Immunol. 2008, 180, 5393–5401.
64. Peluso, I.; Fantini, M.C.; Fina, D.; Caruso, R.; Boirivant, M.; MacDonald, T.T.; Pallone, F.; Monteleone, G. IL-21 counteracts the regulatory T cell-mediated suppression of human CD4+ T lymphocytes. J. Immunol. 2007, 178, 732–739.
65. Chu, Y.W.; Memon, S.A.; Sharrow, S.O.; Hakim, F.T.; Eckhaus, M.; Lucas, P.J.; Gress, R.E. Exogenous IL-7 increases recent thymic emigrants in peripheral lymphoid tissue without enhanced thymic function. Blood 2004, 104, 1110–1119.
66. Jones, J.L.; Compston, D.A.S.; Coles, A.J. Predicting autoimmunity following treatment of multiple sclerosis with alemtuzumab. In Proceedings of the ECTRIMS Meeting, Amsterdam, The Netherlands, 19–22 October 2011.
67. Broadley, S.A.; Deans, J.; Sawcer, S.J.; Clayton, D.; Compston, D.A. Autoimmune disease in first-degree relatives of patients with multiple sclerosis. A UK survey. Brain 2000, 123 Pt 6, 1102–1111.
68. Clatworthy, M.R.; Wallin, E.F.; Jayne, D.R. Anti-glomerular basement membrane disease after alemtuzumab. N. Engl. J. Med. 2008, 359, 768–769.
69. Irizar, H.; Munoz-Culla, M.; Zuriarrain, O.; Goyenechea, E.; Castillo-Trivino, T.; Prada, A.; Saenz-Cuesta, M.; de Juan, D.; Lopez de Munain, A.; Olascoaga, J., et al. HLA-DRB1*15:01 and multiple sclerosis: A female association? Mult. Scler. 2012, 18, 569–577.
70. Cossburn, M.; Pace, A.A.; Jones, J.; Ali, R.; Ingram, G.; Baker, K.; Hirst, C.; Zajicek, J.; Scolding, N.; Boggild, M., et al. Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort. Neurology 2011, 77, 573–579.
71. Mackay, I.R. Clustering and commonalities among autoimmune diseases. J. Autoimmun. 2009, 33, 170–177.
72. Cox, A.L.; Thompson, S.A.; Jones, J.L.; Robertson, V.H.; Hale, G.; Waldmann, H.; Compston, D.A.; Coles, A.J. Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur. J. Immunol. 2005, 35, 3332–3342.
73. Bloom, D.D.; Chang, Z.; Fechner, J.H.; Dar, W.; Polster, S.P.; Pascual, J.; Turka, L.A.; Knechtle, S.J. CD4+CD25+FoxP3+ regulatory T cells increase de novo in kidney transplant patients after immunodepletion with Campath-1H. Am. J. Transplant. 2008, 8, 793–802.
74. Jones, J.L.; Anderson, J.M.; Phuah, C.L.; Fox, E.J.; Selmaj, K.; Margolin, D.; Lake, S.L.; Palmer, J.; Thompson, S.J.; Wilkins, A., et al. Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity. Brain 2010, 133, 2232–2247.
75. Zhang, X.; Tao, Y.; Chopra, M.; Ahn, M.; Marcus, K.L.; Choudhary, N.; Zhu, H.; Markovic-Plese, S. Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis. J. Immunol. 2013, 191, 5867–5874.
76. Stinissen, P.; Hellings, N. Activation of myelin reactive t cells in multiple sclerosis: A possible role for t cell degeneracy? Eur. J. Immunol. 2008, 38, 1190–1193.
77. Turner, M.; Chretien, N.; Havari, E.; LaMorte, M.; Roberts B.; Kaplan J.; Siders, W. Activity of an anti-murine CD52 antibody in experimental autoimmune encephalomyelitis. In Proceedings of the AAN Meeting, New Orleans, LA, USA, 22–27 April 2012.
78. Havari, E.; Turner, M.; Dodge, J.; Treleaven, C.; Shihabuddin, L.; Roberts, B.; Kaplan, J.; Siders, W. Anti-murine CD52 antibody treatment does not adversely affect the migratory ability of immune cells. In Proceedings of the AAN Meeting, Philadelphia, PA, USA, 26 April–3 May 2015.
79. Wang, H.; Dong, J.; Shi, P.; Liu, J.; Zuo, L.; Li, Y.; Gong, J.; Gu, L.; Zhao, J.; Zhang, L., et al. Anti-mouse CD52 monoclonal antibody ameliorates intestinal epithelial barrier function in interleukin-10 knockout mice with spontaneous chronic colitis. Immunology 2015, 144, 254–262.
80. Turner, M.J.; Lamorte, M.J.; Chretien, N.; Havari, E.; Roberts, B.L.; Kaplan, J.M.; Siders, W.M. Immune status following alemtuzumab treatment in human CD52 transgenic mice. J. Neuroimmunol. 2013, 261, 29–36.
81. Turner, M.; Pang, P.T.; Chretien, N.; Havari, E.; LaMorte, M.J.; Oliver, J.; Pande, N.; Masterjohn, E.; Carter, K.; Reczek, D., et al. Reduction of inflammation and preservation of neurological function by anti-CD52 therapy in murine experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2015, 285, 4–12.
82. Baccala, R.; Theofilopoulos, A.N. The new paradigm of T-cell homeostatic proliferation-induced autoimmunity. Trends Immunol. 2005, 26, 5–8.
83. Kassiotis, G.; Zamoyska, R.; Stockinger, B. Involvement of avidity for major histocompatibility complex in homeostasis of naive and memory T cells. J. Exp. Med. 2003, 197, 1007–1016.
84. Guimond, M.; Veenstra, R.G.; Grindler, D.J.; Zhang, H.; Cui, Y.; Murphy, R.D.; Kim, S.Y.; Na, R.; Hennighausen, L.; Kurtulus, S., et al. Interleukin 7 signaling in dendritic cells regulates the homeostatic proliferation and niche size of CD4+ T cells. Nat. Immunol. 2009, 10, 149–157.
85. Sinclair, C.; Bains, I.; Yates, A.J.; Seddon, B. Asymmetric thymocyte death underlies the CD4:CD8 T-cell ratio in the adaptive immune system. Proc. Natl. Acad. Sci. USA 2013, 110, E2905–2914.
86. Gold, R.; Linington, C.; Lassmann, H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 Years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 2006, 129, 1953–1971.
87. Ruck, T.; Bittner, S.; Epping, L.; Herrmann, A.M.; Meuth, S.G. Isolation of primary murine brain microvascular endothelial cells. J. Vis. Exp. 2014, 93, e52204.
88. Fujihara, K.; Nakashima, I. Secondary progression and innate immunity in nmo: A possible link to alemtuzumab therapy? Neurol. Neuroimmunol. Neuroinflammation 2014, 1, e38.
89. Gelfand, J.M.; Cotter, J.; Klingman, J.; Huang, E.J.; Cree, B.A. Massive CNS monocytic infiltration at autopsy in an alemtuzumab-treated patient with nmo. Neurol. Neuroimmunol. Neuroinflammation 2014, 1, e34.
90. Thorne, R.G.; Frey, W.H. 2nd. Delivery of neurotrophic factors to the central nervous system: Pharmacokinetic considerations. Clin. Pharmacokinet. 2001, 40, 907–946.
91. Kousin-Ezewu, O.; Azzopardi, L.; Parker, R.A.; Tuohy, O.; Compston, A.; Coles, A.; Jones, J. Accelerated lymphocyte recovery after alemtuzumab does not predict multiple sclerosis activity. Neurology 2014, 82, 2158–2164.
92. Junker, A.; Ivanidze, J.; Malotka, J.; Eiglmeier, I.; Lassmann, H.; Wekerle, H.; Meinl, E.; Hohlfeld, R.; Dornmair, K. Multiple sclerosis: T-cell receptor expression in distinct brain regions. Brain 2007, 130, 2789–2799.
93. Cohen, J.A.; Barkhof, F.; Comi, G.; Hartung, H.P.; Khatri, B.O.; Montalban, X.; Pelletier, J.; Capra, R.; Gallo, P.; Izquierdo, G., et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med. 2010, 362, 402–415.
94. Kappos, L.; Radue, E.W.; O'Connor, P.; Polman, C.; Hohlfeld, R.; Calabresi, P.; Selmaj, K.; Agoropoulou, C.; Leyk, M.; Zhang-Auberson, L., et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med. 2010, 362, 387–401.
95. Nixon, R.; Bergvall, N.; Tomic, D.; Sfikas, N.; Cutter, G.; Giovannoni, G. No evidence of disease activity: Indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis. Adv. Ther. 2014, 31, 1134–1154.
96. Khatri, B.; Barkhof, F.; Comi, G.; Jin, J.; Francis, G.; Cohen, J. Fingolimod treatment increases the proportion of patients who are free from disease activity in multiple sclerosis compared to IFNβ-1a: Results from a phase 3, active-controlled study (transforms). In Proceedings of the AAN Meeting, New Orleans, LA, USA, 23 April 2012.
97. Polman, C.H.; O’Connor, P.W.; Havrdova, E.; Hutchinson, M.; Kappos, L.; Miller, D.H.; Phillips, J.T.; Lublin, F.D.; Giovannoni, G.; Wajgt, A., et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 2006, 354, 899–910.
98. Havrdova, E.; Galetta, S.; Hutchinson, M.; Stefoski, D.; Bates, D.; Polman, C.H.; O'Connor, P.W.; Giovannoni, G.; Phillips, J.T.; Lublin, F.D., et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: A retrospective analysis of the natalizumab safety and efficacy in relapsing-remitting multiple sclerosis (affirm) study. Lancet Neurol. 2009, 8, 254–260.
99. Azzopardi, L.; Thompson, S.A.; Harding, K.E.; Cossburn, M.; Robertson, N.; Compston, A.; Coles, A.J.; Jones, J.L. Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 2014, 85, 795–798.
100. Cossburn, M.D.; Harding, K.; Ingram, G.; El-Shanawany, T.; Heaps, A.; Pickersgill, T.P.; Jolles, S.; Robertson, N.P. Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosis. Neurology 2013, 80, 55–61.
101. Edwards, K.; LaGanke, C.; Oyuela, P.; Palmer, J.; Margolin, D. Safety of using disease-modifying therapy post-alemtuzumab treatment in patients with relapsing-remitting multiple sclerosis in the core and extensions phases of CAMMS223, CARE-MS I, and CARE-MS II studies. In Proceedings of the AAN Meeting, Philadelphia, PA, USA, 26 April–3 May 2015.
102. Siders, W.M.; Greene, B.; McVie-Wylie, A.; Bailey, M.; Dhawan, V.; Boutin, P.; Best, A.; Lawendowski, C.; Turner, M.; Roberts, B., et al. Characterization of a next-generation anti-CD52 antibody. In Proceedings of the AAN Meeting, Washington, DC, USA, 18–25 April 2015.
103. Somerfield, J.; Hill-Cawthorne, G.A.; Lin, A.; Zandi, M.S.; McCarthy, C.; Jones, J.L.; Willcox, M.; Shaw, D.; Thompson, S.A.; Compston, A.S., et al. A novel strategy to reduce the immunogenicity of biological therapies. J. Immunol. 2010, 185, 763–768.
104. Ruck, T.; Bittner, S.; Kuhlmann, T.; Wiendl, H.; Meuth, S.G. Long-term efficacy of alemtuzumab in polymyositis. Rheumatology (Oxford) 2015, 54, 560–562.
105. Dalakas, M.C.; Rakocevic, G.; Schmidt, J.; Salajegheh, M.; McElroy, B.; Harris-Love, M.O.; Shrader, J.A.; Levy, E.W.; Dambrosia, J.; Kampen, R.L., et al. Effect of alemtuzumab (Campath-1H) in patients with inclusion-body myositis. Brain 2009, 132, 1536–1544.